Autumn J. McRee

3.8k total citations · 1 hit paper
51 papers, 1.5k citations indexed

About

Autumn J. McRee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Autumn J. McRee has authored 51 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Autumn J. McRee's work include Colorectal Cancer Treatments and Studies (29 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Cancer Treatment and Pharmacology (7 papers). Autumn J. McRee is often cited by papers focused on Colorectal Cancer Treatments and Studies (29 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Cancer Treatment and Pharmacology (7 papers). Autumn J. McRee collaborates with scholars based in United States, Japan and Netherlands. Autumn J. McRee's co-authors include Kei Muro, Yung‐Jue Bang, Jonathan Juco, Shilpa Gupta, Hyun Cheol Chung, Minori Koshiji, Chia‐Chi Lin, Kenneth Emancipator, Talia Golan and Dung T. Le and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Autumn J. McRee

49 papers receiving 1.5k citations

Hit Papers

Pembrolizumab for patient... 2016 2026 2019 2022 2016 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
    2016 848 citations Autumn J. McRee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Autumn J. McRee United States 15 1.1k 579 343 313 300 51 1.5k
Shota Fukuoka Japan 14 1.5k 1.4× 553 1.0× 330 1.0× 644 2.1× 226 0.8× 65 1.9k
Hongyong He China 22 784 0.7× 490 0.8× 255 0.7× 685 2.2× 546 1.8× 63 1.7k
Akira Ooki Japan 20 617 0.6× 456 0.8× 331 1.0× 113 0.4× 595 2.0× 98 1.4k
Roberto Pazo-Cid Spain 17 801 0.7× 553 1.0× 295 0.9× 115 0.4× 331 1.1× 69 1.4k
Constantin Volovăț Romania 14 781 0.7× 655 1.1× 273 0.8× 68 0.2× 272 0.9× 43 1.3k
Caterina Vivaldi Italy 18 760 0.7× 512 0.9× 403 1.2× 118 0.4× 346 1.2× 101 1.3k
Philip Agop Philip United States 19 1.3k 1.2× 442 0.8× 381 1.1× 252 0.8× 295 1.0× 113 1.6k
Cinta Hierro Spain 19 700 0.6× 368 0.6× 460 1.3× 169 0.5× 501 1.7× 70 1.3k
Hendrik-Tobias Arkenau United Kingdom 9 1.2k 1.1× 526 0.9× 760 2.2× 202 0.6× 339 1.1× 11 1.6k
Benjamin A. Weinberg United States 18 1.1k 1.0× 450 0.8× 438 1.3× 118 0.4× 293 1.0× 128 1.5k

Countries citing papers authored by Autumn J. McRee

Since Specialization
Citations

This map shows the geographic impact of Autumn J. McRee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Autumn J. McRee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Autumn J. McRee more than expected).

Fields of papers citing papers by Autumn J. McRee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Autumn J. McRee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Autumn J. McRee. The network helps show where Autumn J. McRee may publish in the future.

Co-authorship network of co-authors of Autumn J. McRee

This figure shows the co-authorship network connecting the top 25 collaborators of Autumn J. McRee. A scholar is included among the top collaborators of Autumn J. McRee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Autumn J. McRee. Autumn J. McRee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yu, Shawn, Menggang Yu, David Mauro, et al.. (2024). A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma. The Oncologist. 29(3). 270–e413. 20 indexed citations
3.
Moore, Dominic T., Matthew J. Reilley, Mohamed E. Salem, et al.. (2022). Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer. The Oncologist. 27(12). 1006–e930. 9 indexed citations
4.
Moore, Dominic T., Matthew J. Reilley, Mohamed E. Salem, et al.. (2022). Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology. 40(4_suppl). 88–88.
5.
McRee, Autumn J., Paul R. Helft, William Proctor Harris, et al.. (2022). A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC) with preserved liver function.. Journal of Clinical Oncology. 40(4_suppl). 422–422. 7 indexed citations
6.
Mirlekar, Bhalchandra, Daniel Michaud, Samuel Lee, et al.. (2020). B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Cancer Immunology Research. 8(3). 292–308. 92 indexed citations
7.
Sanoff, Hanna K., Dominic H. Moon, Dominic T. Moore, et al.. (2019). Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Nanomedicine Nanotechnology Biology and Medicine. 18. 189–195. 53 indexed citations
8.
9.
Moon, Dominic H., Autumn J. McRee, A. William Blackstock, et al.. (2017). Phase 1b/2 Study of Neoadjuvant Chemoradiation Therapy With CRLX101 and Capecitabine for Locally Advanced Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics. 99(2). S66–S66. 1 indexed citations
10.
11.
Wang, Andrew Z., Autumn J. McRee, A. William Blackstock, et al.. (2017). Phase Ib/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer.. Journal of Clinical Oncology. 35(15_suppl). e15144–e15144. 4 indexed citations
12.
Laks, Shachar, et al.. (2017). Multidisciplinary Approach to the Management of Esophageal Malignancies. World Journal of Surgery. 41(7). 1726–1733. 5 indexed citations
13.
McRee, Autumn J., P. Kelly Marcom, Dominic T. Moore, et al.. (2017). A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. 18(4). 289–297. 21 indexed citations
14.
Desai, Jayesh, Yong Sang Hong, T.W. Kim, et al.. (2016). Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). Annals of Oncology. 27. vi155–vi155. 5 indexed citations
15.
McRee, Autumn J. & Bert H. O’Neil. (2015). The Role of HIPEC in Gastrointestinal Malignancies: Controversies and Conclusions.. PubMed. 29(7). 523–4, C3. 1 indexed citations
16.
Sanoff, Hanna K., Richard D. Kim, Anastasia Ivanova, et al.. (2015). Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Investigational New Drugs. 33(2). 505–509. 14 indexed citations
17.
McRee, Autumn J., Hanna K. Sanoff, Cheryl A. Carlson, Anastasia Ivanova, & Bert H. O’Neil. (2015). A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Investigational New Drugs. 33(6). 1225–1231. 50 indexed citations
18.
Cleary, James M., Autumn J. McRee, Bert H. O’Neil, et al.. (2014). A phase 1 study of MM-121 (a fully human monoclonal antibody targeting the epidermal growth factor receptor family member ErbB3) in combination with cetuximab and irinotecan in patients with advanced cancers.. Journal of Clinical Oncology. 32(15_suppl). 3076–3076. 10 indexed citations
19.
McRee, Autumn J. & Bert H. O’Neil. (2013). Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer. PubMed. 1(3). 21–29. 1 indexed citations
20.
McRee, Autumn J., et al.. (2011). The role of mTOR and hypoxia pathway activation in promoting tumorigenesis of intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology. 29(4_suppl). 218–218. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shota Fukuoka Breakdown of academic impact, for papers by Hongyong He Breakdown of academic impact, for papers by Akira Ooki Breakdown of academic impact, for papers by Roberto Pazo-Cid Breakdown of academic impact, for papers by Constantin Volovăț Breakdown of academic impact, for papers by Caterina Vivaldi Breakdown of academic impact, for papers by Philip Agop Philip Breakdown of academic impact, for papers by Cinta Hierro Breakdown of academic impact, for papers by Hendrik-Tobias Arkenau Breakdown of academic impact, for papers by Benjamin A. Weinberg
Rankless by CCL
2026